EP1545489A4 - Traitement de la depression consecutive a la douleur - Google Patents

Traitement de la depression consecutive a la douleur

Info

Publication number
EP1545489A4
EP1545489A4 EP03748971A EP03748971A EP1545489A4 EP 1545489 A4 EP1545489 A4 EP 1545489A4 EP 03748971 A EP03748971 A EP 03748971A EP 03748971 A EP03748971 A EP 03748971A EP 1545489 A4 EP1545489 A4 EP 1545489A4
Authority
EP
European Patent Office
Prior art keywords
dsp
pain
treatment
depression secondary
depression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03748971A
Other languages
German (de)
English (en)
Other versions
EP1545489A1 (fr
Inventor
Srinivas G Rao
Jay D Kranzler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cypress Bioscience Inc
Original Assignee
Cypress Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cypress Bioscience Inc filed Critical Cypress Bioscience Inc
Publication of EP1545489A1 publication Critical patent/EP1545489A1/fr
Publication of EP1545489A4 publication Critical patent/EP1545489A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP03748971A 2002-07-24 2003-07-24 Traitement de la depression consecutive a la douleur Withdrawn EP1545489A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US39867602P 2002-07-24 2002-07-24
US398676P 2002-07-24
US44303503P 2003-01-28 2003-01-28
US443035P 2003-01-28
PCT/US2003/023088 WO2004009069A1 (fr) 2002-07-24 2003-07-24 Traitement de la depression consecutive a la douleur

Publications (2)

Publication Number Publication Date
EP1545489A1 EP1545489A1 (fr) 2005-06-29
EP1545489A4 true EP1545489A4 (fr) 2006-08-23

Family

ID=30773102

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03748971A Withdrawn EP1545489A4 (fr) 2002-07-24 2003-07-24 Traitement de la depression consecutive a la douleur

Country Status (6)

Country Link
EP (1) EP1545489A4 (fr)
CN (1) CN1671368A (fr)
AU (1) AU2003268020A1 (fr)
CA (1) CA2493490A1 (fr)
MX (1) MXPA05000566A (fr)
WO (1) WO2004009069A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006099433A1 (fr) 2005-03-14 2006-09-21 Teva Pharmaceutical Industries Ltd. Hydrochlorure de duloxetine pur
FR2978350B1 (fr) 2011-07-28 2013-11-08 Pf Medicament Medicament a base de levomilnacipran pour la rehabilitation fonctionnelle apres accident neurologique aigu
CN112500361B (zh) * 2020-12-27 2023-05-12 甘肃瀚聚药业有限公司 一种(s)-4-苯基-2-恶唑烷酮的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994000114A1 (fr) * 1992-06-23 1994-01-06 Sepracor Inc. Procedes et compositions utilises pour traiter la depression et d'autres affections avec de la sibutramine (-) optiquement pure
WO2003039598A1 (fr) * 2001-11-05 2003-05-15 Cypress Bioscience, Inc. Inhibiteurs selectif de recaptage de la norepinephrine et de la serotonine utilises dans le traitement du syndrome de la fibromyosite, de l'encephalo-myelite myalgique et de la douleur

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2134038C (fr) * 1994-06-16 1997-06-03 David Taiwai Wong Potentialisation des effets de medicaments

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994000114A1 (fr) * 1992-06-23 1994-01-06 Sepracor Inc. Procedes et compositions utilises pour traiter la depression et d'autres affections avec de la sibutramine (-) optiquement pure
WO2003039598A1 (fr) * 2001-11-05 2003-05-15 Cypress Bioscience, Inc. Inhibiteurs selectif de recaptage de la norepinephrine et de la serotonine utilises dans le traitement du syndrome de la fibromyosite, de l'encephalo-myelite myalgique et de la douleur

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"Martindale", 1999, PHARMACEUTICAL PRESS, LONDON, XP002387013, 32 *
BARKIN R L ET AL: "The management challenges of chronic pain: the role of antidepressants.", AMERICAN JOURNAL OF THERAPEUTICS. JAN 2000, vol. 7, no. 1, January 2000 (2000-01-01), pages 31 - 47, XP008065677, ISSN: 1075-2765 *
RUOFF G E: "Depression in the patient with chronic pain.", THE JOURNAL OF FAMILY PRACTICE. DEC 1996, vol. 43, no. 6 Suppl, December 1996 (1996-12-01), pages S25 - S33 ; dis, XP008065739, ISSN: 0094-3509 *
See also references of WO2004009069A1 *
SPENCER CAROLINE M ET AL: "Milnacipran: A review of its use in depression", DRUGS, ADIS INTERNATIONAL LTD, AT, vol. 56, no. 3, September 1998 (1998-09-01), pages 405 - 427, XP008021105, ISSN: 0012-6667 *

Also Published As

Publication number Publication date
CA2493490A1 (fr) 2004-01-29
WO2004009069A1 (fr) 2004-01-29
AU2003268020A1 (en) 2004-02-09
EP1545489A1 (fr) 2005-06-29
CN1671368A (zh) 2005-09-21
MXPA05000566A (es) 2005-08-29

Similar Documents

Publication Publication Date Title
GB2393860B (en) Improvements relating to retention of rechargeable devices
GB0313045D0 (en) Improvements relating to charging of devices
AU2003239568A1 (en) Pyrrolotriazinone compounds and their use to treat diseases
EP1567157A4 (fr) Methodes d'utilisation et compositions recourant a des composes immunomodulatoires pour le traitement et la gestion de syndromes myeloproliferatifs
GB0015745D0 (en) Treatment of bone diseases
PL375784A1 (en) Use of erythopoietin
AU2003295336A1 (en) Use of etodoclac to treat hyperplasia
IL160928A0 (en) Use of histamine to treat liver disease
IL166016A0 (en) Topical treatment of skin diseases
GB0213869D0 (en) The treatment of pain
GB2408558B (en) Treatment of pipes
GB0211295D0 (en) Treatment of pain
EP1525216A4 (fr) Therapie combinee pour le traitement d'infection vih
EP1404308A4 (fr) Traitement de troubles secondaires provoques par des deficiences organiques
GB0218798D0 (en) Improvements to determination of ovulation
EP1545489A4 (fr) Traitement de la depression consecutive a la douleur
AU2003241346A8 (en) Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer
AU2003222250A1 (en) Treatment of autoimmune diseases
GB0217493D0 (en) Novel methods of treatment
AU2003270615A8 (en) Treatment of steatosis using hyperthermia
AU2003207315A1 (en) Treatment of muscle damage
GB0221712D0 (en) Methods of treatment
AU2002360523A8 (en) Compounds to treat hiv infection and aids
IL164099A0 (en) Use of interleukin-19 to treat cervical cancer
AU2003272327A8 (en) Methods of bone healing

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050218

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 25/24 20060101ALI20060712BHEP

Ipc: A61P 25/02 20060101ALI20060712BHEP

Ipc: A61K 31/165 20060101AFI20040211BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20060724

17Q First examination report despatched

Effective date: 20061025

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080809